<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50131">5-Aza-2'-deoxycytidine</z:chebi>, a DNA-hypomethylating agent, can induce clinical remissions in patients with high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>During treatment an increase in platelet count is frequently the first positive event to be seen </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we analyzed the platelet response of patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> on low-dose <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>We evaluated 162 from the 170 patients entered in three consecutive Phase II studies </plain></SENT>
<SENT sid="4" pm="."><plain>One hundred twenty-six of them were thrombocytopenic at start of the therapy </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had an IPSS risk score of Intermediate I or higher </plain></SENT>
<SENT sid="6" pm="."><plain>A rise in platelet count preceded a good trilineage response </plain></SENT>
<SENT sid="7" pm="."><plain>In 58% of the thrombocytopenic patients a platelet response was already seen after one cycle of therapy </plain></SENT>
<SENT sid="8" pm="."><plain>During therapy 69% of the patients with a <z:hpo ids='HP_0001873'>low platelet count</z:hpo> showed a response </plain></SENT>
<SENT sid="9" pm="."><plain>Due to disease progression the final response rate was 63% in thrombocytopenic patients </plain></SENT>
<SENT sid="10" pm="."><plain>No correlation was found between the platelet response and either the presence or absence of an adequate number of megakaryocytes or serum thrombopoietin levels </plain></SENT>
<SENT sid="11" pm="."><plain>However, platelet response strongly predicted for overall survival (P &lt; 0.0001) </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="50131">5-Aza-2'-deoxycytidine</z:chebi> has a clinically significant, often long lasting, effect on the platelet count in a substantial number of high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>